Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Curebase raises $40 million in Series B funding round 

By Brian Buntz | May 5, 2022

CurebaseDecentralized clinical trial specialist Curebase said today that it has secured $40 million in Series B funding.

The lead investor in the round was Industry Ventures. Other investors contributing to the round include Acrew Capital, World Innovation Lab, Positive Sum, Gilead Sciences (Nasdaq:GILD) and existing investors GGV Capital, Bold Capital and Xfund.

The San Francisco–based company has worked to popularize the concept of “bring your own physician” (BYOP) to make clinical trials available to patients regardless of location.

“Traditional clinical trials at big hospitals tend to be slower, more expensive, less diverse,” Curebase CEO Tom Lemberg said in an interview. “Our objective as a company is to bring the trial to the patient both at home and with their own physician.”

Tom Lemberg

Tom Lemberg

Curebase says its decentralized approach can accelerate recruiting, facilitate clinical trial diversity and ultimately improve clinical research.

The company has surpassed industry averages on diversity by a wide margin while also driving faster recruitment, Lemberg said. “We do over 200 patients per month and recruitment into the majority of our studies,” he noted.

Lemberg says its approach also optimizes patient experience. For example, the company recently was involved in a pivotal gastrointestinal study supporting FDA authorization with 97% patient satisfaction.

The company plans on using the funding to expand its development of sophisticated site and community healthcare interfaces, clinical software and services and add new capabilities for interventional drug sponsors and global studies. Lemberg plans to continue optimizing the patient experience.

“We want to make the experience for patients incredibly simple — consumer-grade and as easy as anything else you do on your smartphone,” he said.

“The second thing is we are not just virtual, and we are investing even more with the Series B in our site operating system,” Lemberg continued. “We think there is a really strong role for the community physician.”

Curebase has more than 100 community sites that use its platform or site operating system. Its platform allows sites to “participate in a very low burden way,” Lemberg said. “For example, we can work with urgent cares, primary cares, OB-GYNs and local specialists.”

In addition, the company will use the funding to expand its virtual site services. It currently has virtual principal investigators and virtual research coordinators. “We can operate in a very end-to-end way. We can take a trial from start to finish,” Lemberg said

Curebase was founded in 2018. The company has raised $59 million to date.


Filed Under: clinical trials, Drug Discovery
Tagged With: Curebase, decentralized clinical trial, Tom Lemberg
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
How biosimulation and virtual trials can bust through clinical trial roadblocks
Complexity’s counterpoint: Understanding protocol optimization 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE